{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:10Z","timestamp":1793725990677,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previously lacking in the literature, we describe longitudinal patterns of anemia prescriptions for non-dialysis-dependent chronic kidney disease (NDD-CKD) patients under nephrologist care. We analyzed data from 2818 Stage 3-5 NDD-CKD patients from Brazil, Germany, and the US, na\u00efve to anemia medications (oral iron, intravenous [IV] iron, or erythropoiesis stimulating agent [ESA]) at enrollment in the CKDopps. We report the cumulative incidence function (CIF) of medication initiation stratified by baseline characteristics. Even in patients with hemoglobin (Hb)\u2009&lt;\u200910\u00a0g\/dL, the CIF at 12\u00a0months for any anemia medication was 40%, and 28% for ESAs. Patients with TSAT\u2009&lt;\u200920% had a CIF of 26% and 6% for oral and IV iron, respectively. Heart failure was associated with earlier initiation of anemia medications. IV iron was prescribed to\u2009&lt;\u200910% of patients with iron deficiency. Only 40% of patients with Hb\u2009&lt;\u200910\u00a0g\/dL received any anemia medication within a year. Discontinuation of anemia treatment was very common. Anemia treatment is initiated in a limited number of NDD-CKD patients, even in those with guideline-based indications to treat. Hemoglobin trajectory and a history of heart failure appear to guide treatment start. These results support the concept that anemia is sub-optimally managed among NDD-CKD patients in the real-world setting.<\/jats:p>","DOI":"10.1038\/s41598-020-79254-6","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:09:05Z","timestamp":1611054545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps"],"prefix":"10.1038","volume":"11","author":[{"given":"Marcelo Barreto","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarcy","family":"Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murilo","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Pisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Hedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Alberto","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Reichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sloand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Waechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M. Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"79254_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/kisup.2012.35","volume":"2","author":"K Chapter","year":"2012","unstructured":"Chapter, K. KDIGO clinical practice guideline for anemia in chronic kidney disease. Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int. Suppl. 2, 299\u2013310 (2012).","journal-title":"Kidney Int. Suppl."},{"key":"79254_CR2","unstructured":"United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, https:\/\/www.usrds.org\/adr.aspx (2017)."},{"key":"79254_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt, J. L. & Lin, H. Y. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 23, 1631\u20131634. https:\/\/doi.org\/10.1681\/ASN.2011111078 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"79254_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ndt\/gft443","volume":"29","author":"K Zumbrennen-Bullough","year":"2014","unstructured":"Zumbrennen-Bullough, K. & Babitt, J. L. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol. Dial. Transplant. 29, 263\u2013273. https:\/\/doi.org\/10.1093\/ndt\/gft443 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"79254_CR5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/ndt\/gft533","volume":"29","author":"MC de Goeij","year":"2014","unstructured":"de Goeij, M. C. et al. Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care. Nephrol. Dial. Transplant. 29, 1391\u20131398 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"79254_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019\u20132032. https:\/\/doi.org\/10.1056\/NEJMoa0907845 (2009).","journal-title":"N. Engl. J. Med."},{"key":"79254_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.163","author":"R Agarwal","year":"2015","unstructured":"Agarwal, R., Kusek, J. W. & Pappas, M. K. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. https:\/\/doi.org\/10.1038\/ki.2015.163 (2015).","journal-title":"Kidney Int."},{"key":"79254_CR8","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085\u20132098. https:\/\/doi.org\/10.1056\/NEJMoa065485 (2006).","journal-title":"N. Engl. J. Med."},{"key":"79254_CR9","unstructured":"Alert, F. D. A Information for healthcare professionals: erythropoiesis stimulating agents (ESA){Aranesp [darbepoetin], Epogen [epoetin alfa] and Procrit [epoetin alfa]). Rockville MD: Food and Drug Aministration, March 9, 2007. Archived at: https:\/\/wayback.archiveit.org\/7993\/20170723113601\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm126481.htm (2009)."},{"key":"79254_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2, 279\u2013335 (2012).","journal-title":"Kidney Int."},{"key":"79254_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz2091","author":"MMY Wong","year":"2019","unstructured":"Wong, M. M. Y. et al. Anemia and iron deficiency among chronic kidney disease Stages 3\u20135ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin. Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfz2091 (2019).","journal-title":"Clin. Kidney J."},{"key":"79254_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2215\/CJN.01670408","volume":"4","author":"S Fishbane","year":"2009","unstructured":"Fishbane, S., Pollack, S., Feldman, H. I. & Joffe, M. M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988\u20132004. Clin. J. Am. Soc. Nephrol. 4, 57\u201361. https:\/\/doi.org\/10.2215\/CJN.01670408 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"79254_CR13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli, F. et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol. Dial. Transplant. 28, 1346\u20131359. https:\/\/doi.org\/10.1093\/ndt\/gft033 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"79254_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.267","author":"BJ Manns","year":"2008","unstructured":"Manns, B. J. et al. Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease. Kidney Int. Suppl. https:\/\/doi.org\/10.1038\/ki.2008.267 (2008).","journal-title":"Kidney Int. Suppl."},{"key":"79254_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.ajkd.2016.03.414","volume":"68","author":"L Mariani","year":"2016","unstructured":"Mariani, L. et al. The CKD outcomes and practice patterns study (CKDopps): rationale and methods. Am. J. Kidney Dis. 68, 402\u2013413. https:\/\/doi.org\/10.1053\/j.ajkd.2016.03.414 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"79254_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"79254_CR17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"79254_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.ajkd.2018.10.006","volume":"73","author":"FR McCausland","year":"2019","unstructured":"McCausland, F. R. et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). Am. J. Kidney Dis. 73, 309\u2013315. https:\/\/doi.org\/10.1053\/j.ajkd.2018.10.006 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"79254_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich, D., Rozen-Zvi, B., Avni, T., Gafter, U. & Gafter-Gvili, A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am. J. Kidney Dis. 68, 677\u2013690. https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.018 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"79254_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","volume":"65","author":"GA Block","year":"2015","unstructured":"Block, G. A. et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3\u20135. Am. J. Kidney Dis. 65, 728\u2013736. https:\/\/doi.org\/10.1053\/j.ajkd.2014.10.014 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"79254_CR21","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall, I. C. et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 29, 2075\u20132084 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"79254_CR22","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1401038","volume":"372","author":"C Camaschella","year":"2015","unstructured":"Camaschella, C. Iron-deficiency anemia. N. Engl. J. Med. 372, 1832\u20131843. https:\/\/doi.org\/10.1056\/NEJMra1401038 (2015).","journal-title":"N. Engl. J. Med."},{"key":"79254_CR23","doi-asserted-by":"publisher","first-page":"c55","DOI":"10.1159\/000085049","volume":"100","author":"C Charytan","year":"2005","unstructured":"Charytan, C., Qunibi, W. & Bailie, G. R. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron. Clin. Pract. 100, c55-62. https:\/\/doi.org\/10.1159\/000085049 (2005).","journal-title":"Nephron. Clin. Pract."},{"key":"79254_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.275","author":"GR Bailie","year":"2014","unstructured":"Bailie, G. R. et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. https:\/\/doi.org\/10.1038\/ki.2014.275 (2014).","journal-title":"Kidney Int."},{"key":"79254_CR25","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1093\/ndt\/gft062","volume":"28","author":"GR Bailie","year":"2013","unstructured":"Bailie, G. R. et al. Variation in intravenous iron use internationally and over time: the dialysis outcomes and practice patterns study (DOPPS). Nephrol. Dial. Transplant. 28, 2570\u20132579. https:\/\/doi.org\/10.1093\/ndt\/gft062 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"79254_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz065","author":"A Karaboyas","year":"2019","unstructured":"Karaboyas, A. et al. Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. Clin. Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfz065 (2019).","journal-title":"Clin. Kidney J."},{"key":"79254_CR27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.05.004","author":"DT Gilbertson","year":"2013","unstructured":"Gilbertson, D. T., Monda, K. L., Bradbury, B. D. & Collins, A. J. RBC transfusions among hemodialysis patients (1999\u20132010): influence of hemoglobin concentrations below 10 g\/dL. Am. J. Kidney Dis. https:\/\/doi.org\/10.1053\/j.ajkd.2013.05.004 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"79254_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2215\/CJN.06020809","volume":"5","author":"EV Lawler","year":"2010","unstructured":"Lawler, E. V., Bradbury, B. D., Fonda, J. R., Gaziano, J. M. & Gagnon, D. R. Transfusion burden among patients with chronic kidney disease and anemia. Clin. J. Am. Soc. Nephrol. CJASN 5, 667\u2013672. https:\/\/doi.org\/10.2215\/CJN.06020809 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"79254_CR29","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Drueke","year":"2006","unstructured":"Drueke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071\u20132084. https:\/\/doi.org\/10.1056\/NEJMoa062276 (2006).","journal-title":"N. Engl. J. Med."},{"key":"79254_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1159\/000351175","volume":"37","author":"PA McCullough","year":"2013","unstructured":"McCullough, P. A. et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am. J. Nephrol. 37, 549\u2013558. https:\/\/doi.org\/10.1159\/000351175 (2013).","journal-title":"Am. J. Nephrol."},{"key":"79254_CR31","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1161\/CIRCULATIONAHA.111.030411","volume":"124","author":"H Skali","year":"2011","unstructured":"Skali, H. et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 124, 2903\u20132908. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.030411 (2011).","journal-title":"Circulation"},{"key":"79254_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl. J. Med. 339, 584\u2013590. https:\/\/doi.org\/10.1056\/NEJM199808273390903 (1998).","journal-title":"New Engl. J. Med."},{"key":"79254_CR33","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","volume":"317","author":"GD Lewis","year":"2017","unstructured":"Lewis, G. D. et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 317, 1958\u20131966. https:\/\/doi.org\/10.1001\/jama.2017.5427 (2017).","journal-title":"JAMA"},{"key":"79254_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ejhf.229","volume":"17","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski, P. et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur. J. Heart Fail. 17, 329\u2013339. https:\/\/doi.org\/10.1002\/ejhf.229 (2015).","journal-title":"Eur. J. Heart Fail."},{"key":"79254_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ejhf.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker, S. D. et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur. J. Heart Fail. 20, 125\u2013133. https:\/\/doi.org\/10.1002\/ejhf.823 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"79254_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10741-008-9089-7","volume":"13","author":"YD Tang","year":"2008","unstructured":"Tang, Y. D. & Katz, S. D. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail. Rev. 13, 387\u2013392. https:\/\/doi.org\/10.1007\/s10741-008-9089-7 (2008).","journal-title":"Heart Fail. Rev."},{"key":"79254_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ejhf.84","volume":"16","author":"IT Klip","year":"2014","unstructured":"Klip, I. T. et al. The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. Eur. J. Heart Fail. 16, 655\u2013662. https:\/\/doi.org\/10.1002\/ejhf.84 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"79254_CR38","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","volume":"95","author":"AA House","year":"2019","unstructured":"House, A. A. et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 95, 1304\u20131317. https:\/\/doi.org\/10.1016\/j.kint.2019.02.022 (2019).","journal-title":"Kidney Int."},{"key":"79254_CR39","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/j.1523-1755.2005.00226.x","volume":"67","author":"TM El-Achkar","year":"2005","unstructured":"El-Achkar, T. M. et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. Kidney Int. 67, 1483\u20131488 (2005).","journal-title":"Kidney Int."},{"key":"79254_CR40","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ndt\/gfn653","volume":"24","author":"F Locatelli","year":"2009","unstructured":"Locatelli, F., Covic, A., Eckardt, K. U., Wiecek, A. & Vanholder, R. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol. Dial. Transplant. 24, 348\u2013354. https:\/\/doi.org\/10.1093\/ndt\/gfn653 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"79254_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1744-9987.2010.00836.x","volume":"14","author":"Y Tsubakihara","year":"2010","unstructured":"Tsubakihara, Y. et al. 2008 Japanese Society for dialysis therapy: guidelines for renal anemia in chronic kidney disease. Ther. Apher. Dial. 14, 240\u2013275. https:\/\/doi.org\/10.1111\/j.1744-9987.2010.00836.x (2010).","journal-title":"Ther. Apher. Dial."},{"key":"79254_CR42","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/ndt\/gfw123.05","volume":"31","author":"MM Wong","year":"2016","unstructured":"Wong, M. M. et al. SO037 ANemia prevalence and treatment among patients with chronic kidney disease stage 3\u20135: data from the chronic kidney disease outcomes and practice patterns study (CKDOPPS). Nephrol. Dial. Transplant. 31, i16\u2013i17 (2016).","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79254-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79254-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79254-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:11:10Z","timestamp":1724346670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79254-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["79254"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-79254-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"James Sloand is employed by and owns stock in AstraZeneca; he owns stock options and shares in Baxter Healthcare Corporation. Michelle Wong was previously a consultant for Arbor Research Collaborative for Health; she has received research funding from Michael Smith Foundation for Health Research. Glen James is an employee of AstraZeneca who receives salary and owns stock. Ziad Massy reports grants and other from Amgen, grants and other from Sanofi-Genzyme, grants from French Government , grants from MSD, grants from GSK, grants from Lilly, grants from FMC, grants and other from Baxter, grants from Outsuka, other from Daichi, other from Astellas , outside the submitted work. Helmut Reichel reports honoraria from Vifor, Amgen, Hexal. Bryce Foote is an employee of Keryx Biopharmaceuticals. Katarina Hedman is employed by AstraZeneca and owns shares of AstraZeneca. Sandra Waechter is an employee of Vifor Pharma. Bruce M. Robinson, Jarcy Zee, Charlotte Tu, Murilo Guedes, Marcelo Barreto Lopes, Ronald L Pisoni, and Roberto Pecoits-Filho are employees of Arbor Research Collaborative for Health, which administers the DOPPS. Antonio A. Lopes does not have any conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1784"}}